How Long Does Nucynta Stay in Your System?

Nucynta can remain at testable levels in the urine for up to three to four days following the time of last dose. Nucynta has a half-life of roughly four hours. This is the amount of time it takes for half of the drug’s contents to be eliminated from the body. More than 95% of Nucynta is excreted within the first 24 hours.

Nucynta is an analgesic opioid that’s prescribed to treat moderate to severe pain following traumatic injury. Nucynta is a brand name of tapentadol that is taken orally as a liquid solution. It is also recommended to treat chronic pain from diabetic neuropathy. Nucynta has a moderate potency when compared to most other synthetic opioids. For reference, its potency lies somewhere in between tramadol and morphine. Nucynta is approximately as powerful at relieving pain as oxycodone, despite the fact that Nucynta’s side effects are significantly less severe than those associated with oxycodone.
Nucynta was approved for distribution in the United States by the Federal Drug Administration (FDA) in 2008. It became available in Australia in 2010, and in the UK in 2011. Nucynta is classified as a Schedule II substance in the US. The FDA considers Nucynta to have a high misuse potential despite the World Health Organization claiming that there is little evidence on which to base this judgment. Animal trials suggest that Nucynta has a reduced misuse potential compared to other opioid pain relievers.
When taken recreationally, Nucynta is commonly mixed with other opioids and central nervous system depressants. The concomitant use of Nucynta with other opioids can lead to potentially life-threatening complications including liver toxicity, severe respiratory depression, and catastrophic organ failure.

Nucynta should not be taken concurrently with muscle relaxants, tranquilizers, anxiolytics, benzodiazepines, non-benzodiazepine sedative/hypnotics, antipsychotics, or general anesthetics. The combination of Nucynta and alcohol can result in the conflicting enzymes in the liver. This can lead to extended clearance rates and elevated concentrations of Nucynta in the blood plasma. Extended clearance times and elevated plasma concentrations greatly increase the risk of opioid toxicity and overdose.

Nucynta should also not be combined with serotonergic drugs like selective serotonin reuptake inhibitors (SSRIs), tricyclics, or MAO inhibitors uses to treat depression. The concomitant consumption of Nucynta with the substances can lead to a potentially fatal condition of serotonin overload. Serotonin syndrome can cause irreversible psychosis.

Nucynta is similar to the synthetic opioid tramadol. Tramadol activates opioid receptors while inhibiting the reuptake of serotonin. Instead of inhibiting the reuptake of serotonin, Nucynta inhibits the reuptake of the neurotransmitter norepinephrine. By inhibiting the reuptake of norepinephrine, Nucynta increases its activity in the brain.

Nucynta achieves its pain-relieving effects by binding to specific opioid receptors. Nucynta does not rely on the body metabolizing it to achieve its therapeutic effects. This makes Nucynta especially useful in treating pain in patients who are genetically predisposed to poorly metabolizing other opioids. Most opioids rely heavily on the liver to process the drug into metabolites which can then be used by the body. Nucynta can bypass this mechanism.

Common side effects of Nucynta include drowsiness, dizziness, nausea, vomiting, dry mouth, fatigue, sleepiness, itchiness, and headache.

Nucynta has an apparent half-life of 3.93 hours following oral administration. The total clearance rate of Nucynta is 1,530 plus or minus 177 mL per minute. 95% of Nucynta and its metabolites are excreted within 24 hours of the time of ingestion.
The patient’s age, weight, body fat percentage, kidney and liver health, overall physical status, opioid tolerance, and genetic tendencies all can impact the rate at which Nucynta is eliminated from the body. In general, younger patients tend to metabolize the drug more rapidly due to an overall faster metabolism.

Elderly patients tend to require lower doses due to suboptimal functioning of the liver and kidneys which are responsible for processing the drug. Certain individuals are genetically predisposed to longer elimination times due to a lack of the enzymes required to metabolize Nucynta. Enzymatic complications are less common with Nucynta when compared with other synthetic opioids.

Nucynta may be detected in the urine for up to four days following the time of ingestion. This window of time can vary between patients. Individuals who take higher and more frequent doses of Nucynta are more likely to take longer to clear the drug from their system. Nucynta can be detected in hair follicle tests for up to 90 days following the time of the last dose.

If you or someone you love is struggling with opioid misuse, The Recovery Village is available to answer any questions you may have.

Medical Disclaimer: The Recovery Village aims to improve the quality of life for people struggling with a substance use or mental health disorder with fact-based content about the nature of behavioral health conditions, treatment options and their related outcomes. We publish material that is researched, cited, edited and reviewed by licensed medical professionals. The information we provide is not intended to be a substitute for professional medical advice, diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare provider.